The most important upcoming catalyst in neuroscience is Eli Lilly's TRAILBLAZER-ALZ 3 study, which aims to prevent Alzheimer's in at-risk patients. A positive result is expected to show a much larger effect size than seen in treating existing disease, potentially creating a massive new market and shifting the entire neurodegenerative paradigm.

Developing a second oral peptide isn't a simple 'copy-and-paste' of the first. The team uses the analogy of having a second child: while past experience makes them faster and more efficient, each new molecule presents its own unique challenges that must be solved from scratch. This highlights the nuanced reality of platform technology leverage.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

The GSK3 inhibitor was developed for CNS diseases, requiring high specificity and the ability to cross the blood-brain barrier. These same pharmaceutical characteristics—potency and lipophilicity—proved highly advantageous for treating cancer, demonstrating an unexpected but effective therapeutic pivot from neuroscience to oncology.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.

After Novo Nordisk's GLP-1 trial in Alzheimer's failed to show clinical benefit despite a 10% biomarker improvement, Coya is pursuing a combination therapy. They theorize that adding low-dose IL-2 can synergistically boost biomarkers to the 25-30% range, a level they believe is necessary to achieve clinically meaningful effects.

Xenon successfully de-risked the biologically validated but previously failed KV7 epilepsy target. They designed a new chemical structure that prevents dimerization, the molecular action responsible for the severe side effects that caused GSK's earlier drug to be withdrawn. This showcases a strategy of innovating on chemistry to solve known safety issues of a proven mechanism.